Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Patients are paying more out of their pockets for drugs. Photo: Jeffrey Greenberg / UIG via Getty Images

Health insurers and pharmacy benefit managers are blasting a proposed federal policy that would lower what patients pay out of pocket when they pick up their prescriptions, saying it coddles the pharmaceutical industry. But drug companies are firing back, accusing insurers and PBMs of keeping larger drug discounts for themselves and screwing over consumers in the process.

Get smart: Patients are caught in the middle of yet another health care industry gunfight.

The Centers for Medicare & Medicaid Services received more than 1,600 comments on a proposed rule that would make major changes to Medicare Advantage and the Medicare Part D drug program. One of the most contentious suggestions would mandate a certain amount of drug company rebates be applied to what people pay at the point of sale at pharmacies.

  • The issue: Say a drug has a list price of $1,000, and an insurer or PBM negotiates that down to $500. However, consumers have to pay coinsurance rates and deductibles based on the $1,000 list price, not the discounted amount. This has led to price shock for many people picking up their prescriptions, and more people are having trouble affording their medicines.
  • The federal government asked whether it would be a good idea to require insurers and PBMs that sell Medicare Part D plans to use a portion of those negotiated drug rebates to lower what people pay at the pharmacy counter.

Behind the curtain: The insurance and pharmacy benefit management industries are up in arms, and have no qualms about attacking drug makers. Insurers and PBMs keep some of the drug rebates for themselves, but they say those savings also go toward lowering insurance premiums.

  • If they are forced to use rebates to lower consumers' out-of-pocket costs, they will raise premiums in response, which will waste taxpayer money that funds Medicare Part D, according to lobbying groups and companies.
  • America's Health Insurance Plans and other insurer groups said the policy doesn't address the "root cause" of skyrocketing drug costs: "excessive list prices for drugs and excessive price increases that are set solely by and fully within the control of manufacturers."
  • It may encourage a race to the bottom among drug companies and make it easier for them to scale back their rebates, according to Express Scripts, one of the largest PBMs in the country.
  • The Pharmaceutical Care Management Association, which lobbies on behalf of PBMs, argued such a proposal violates trade secrets law.
  • Aetna, CVS Health and UnitedHealth Group all bashed the policy, too. Aetna said drug companies would reap twice as much in savings over consumers.
  • The Pharmaceutical Research and Manufacturers of America did its own math and said pushing rebates to the point of sale would save Medicare and consumers money, but admitted premiums would go up.

Between the lines: Both sides catch parts of the truth, which is best summarized by the independent Medicare Payment Advisory Commission. The policy would do nothing to lower the sticker price of drugs, and it would lead to higher drug premiums for seniors and disabled people. But health plans and PBMs profit a lot from the current setup, and the secretive nature of drug rebates keeps patients in the dark.

There's no signal or guarantee the federal proposal would move the needle on Medicare's drug affordability.

The bottom line: While the various health care camps fight to either keep the status quo or push for vested interests, drug prices continue to hammer the wallets of Medicare patients who need their medications.

Go deeper

Top economic regulators stressed by vacancies

Illustration: Annelise Capossela/Axios

The boom times are all around us (from corporate deal sprees to the breakneck rise of cryptocurrency) — and the agencies in charge are stretched thin trying to police it.

Why it matters: Overwhelmed staff and a slew of vacant posts could set back President Biden's big regulatory agenda.

GOP Sen. Chuck Grassley announces run for re-election

Photo: Greg Nash/The Hill/Bloomberg via Getty Images

Sen. Chuck Grassley (R-Iowa), the longest-serving Senate Republican, announced on Friday that he's running for re-election in 2022.

Why it matters: The GOP is looking to regain control of both chambers of Congress in the upcoming midterm elections. Several Republicans had urged the 88-year-old senator to run to avoid another retirement after five incumbent senators said they wouldn't seek re-election.

China deems all cryptocurrency transactions illegal

A person walking past China's central bank in Beijing in August 2007. Photo: Teh Eng Koon/AFP via Getty Images

China's central bank declared on Friday that all cryptocurrencies are illegal, banning crypto-related transactions and cryptocurrency mining, according to Reuters.

Why it matters: China's government is now following through with its goal of cracking down on unofficial virtual currencies, which it has said are a financial, social and national security risk and a contributor to global warming.